ASH 2020 Virtual Conference

ASH2020

 

Originally to be held in San Diego, California, the 62nd ASH Annual Meeting and Exposition organised by the American Society of Hematology will be presented as an all-virtual event on December 5-8, 2020, given the continuing threat of the COVID-19 pandemic.

This year we will be attending this important meeting for the CML patient advocacy community for an invaluable educational experience and the opportunity to review many scientific abstracts highlighting updates on chronic myeloid leukemia.

We have prepared a selection of the most critical presentations on CML to be followed by the CML patient advocates. Please, note all times listed are in Pacific Time (PST):


- Saturday 5th December -

7:30 AM- 9:00 AM PST

632 Chronic Myeloid Leukemia: Therapy— Building The Future CML. Oral Abstracts

 

  • 45 Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212. Itaru Matsumura, MD, Ph.D.
  • 46 Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Before Trial. Tim H Brümmendorf, MD.
  • 47 Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Massimiliano Bonifacio, MD.
  • 48 Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CMLJorge E. Cortes, MD.
  • 49 Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. Naranie Shanmuganathan, FRACP, FRCPA, MBBS.
  • 50 Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Patrizia Pregno.

 

12:00 PM-12:45 PM PST

EDUCATION PROGRAM. Handling Challenging Questions in the Management of CML. Live Q&A.
  • First Generation vs. Second Generation TKI - Which is Best At Diagnosis of Chronic Phase CML? Vivian G. Oehler, MD.
  • When is it safe to stop TKIs? Delphine Rea, MD, Ph.D.
  • How to manage CML patients with comorbidities? Jorge E. Cortes, MD.

12:00 PM PST

Session: 906-Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management And Outcome, Oral Abstracts:

 

  • 12:45 PM 216 Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy. Ehab L. Atallah, MD. 

Poster I. 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy.

  • Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Immunolipsome
  • Comparison of the Transcriptomic Signatures in Pediatric and Adult CML

Poster I. 632. Chronic Myeloid Leukemia: Therapy.

Poster I. 906. Outcomes Research – Malignant Conditions (Myeloid Disease).

 

- Sunday 6th December -

 

9:30 AM-11:00 AM PST

Special Interest Session: The 2020 Pandemic: Latest Insights on COVID-19. 

  • Do COVID-19 Patients Face Increased Risk of Thrombosis? Saskia Middeldorp, MD, PhD
  • How Can Community-Based Surveillance Strategies for Sars-Cov-2 Inform Pandemic Planning? Helen Chu, MD, MPH

11:00 AM- 12:00 PM PST

Product Theaters, Pfizer

  • A Treatment Option for Adult Patients with Newly Diagnosed CP Ph+ CML or Patients with CML Resistant/Intolerant to Prior TKI Therapy. Jasmeet Anand, PharmD

Poster II. 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy.

  • Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML
  • Dasatinib Promotes the Maduration of Healthy Donors and Chronic Myelogeneous Leukemia Patients Derived Dendritic Cells

Poster II. 632. Chronic Myeloid Leukemia: Therapy.

Poster II. 901.  Health Services Research – Non-Malignant Conditions

  • 2477 Clinical & Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice in Israel. Co-author, Giora Sharf, CML Advocates Network co-founder.

Poster II. 603. Oncogenes and Tumor Suppressors

  • 1875 Examination of Clinically_Derived p210 BCR/ABL Rhogef Mutations in a Murine Bone Marrow Transplantation Model of CMLBryan T. Ciccarelli, MD, Ph.D.

 

- Monday 7th December -

7:00 AM- 7:45 AM PST

Education Program: Improving Symptom Control for Children with Hematological Malignancies - Live Q&A

  • Dr. Lillian Sung will describe the importance of symptom control in children with cancer, and approaches to identify symptoms amenable to clinical implementation.
  • Dr. Tamara P. Miller will discuss the current method of capturing treatment toxicities on pediatric hematology clinical trials, under-reporting of toxicities using the existing system, and the specific challenges related to pediatric trials.
  • Dr. Robert Phillips will discuss approaches to control toxicity and aversive symptoms, from preventative strategies to therapeutic approaches.

9:00 AM PST

903 Health Services Research—Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies, Oral Abstracts:
  • 620 Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Rong Wang, PhD

11:30 AM- 1:00 PM PST

632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond, Oral Abstracts.
  • 647 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. Hagop M. Kantarjian, MD
  • 648 Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS). Monica Bocchia
  • 649 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Delphine Rea, MD, PhD
  • 650 Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Jorge E. Cortes, MD
  • 651 Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. Qian Jiang, MD
  • 652 Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including PonatinibJorge E. Cortes, MD

1:30 PM-3:00 PM PST

631 CML: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Progression in CML, Oral Abstracts.
 
Poster III. 632. Chronic Myeloid Leukemia: Therapy.

 

- Tuesday 8th December -

7:30 AM - 9:30 AM PST

Late-breaking Abstracts

LBA-4 Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIsAndreas Hochhaus, MD.

 

 

Follow the conversation on our social media channels with #CML #ASH20 #PatientAdvocacy!

ASH20_2

 

 

Please donate!

Please donate!

LogIn

EU e-Privacy Directive